about o2h kickstarter
o2h Discovery is a fully integrated Anglo-Indian CRO with a global client base. The o2h kickstarter competition has been developed to provide a boost to small molecule focused biotechnology companies which have usually raised some initial funding and need to supercharge their chemistry efforts to meet their next funding milestone. We at o2h Discovery are driven by innovations in medicinal chemistry drug discovery research that develops new drugs and therapies for various diseases, satisfying the unmet needs for healthy human life and well-being.
winners feedback from the first competition
More than 30 companies applied from across the globe, and here are the six companies who made it to the winners list.

Dr Neil Benson
CEO

The kickstarter competition was transformative for Sevenless. We were able to effectively put 10 full time FTEs on our lead optimization program, which delivered novel chemistry ahead of schedule. The progress was outstanding and the o2h team a pleasure to work with. Kickstarter did for us exactly as it’s name suggests. We are now looking to move a drug candidate forward through IND enabling studies and towards Phase I clinical trials.

Jason Rutt
CEO

Running a chemistry program is always a challenging sell to investors. The o2h kickstarter award did several things. It defrayed the cost of the program. It gave us access to a large team of skilled synthetic chemists. It allowed us to partner with experienced medicinal chemists. Finally o2hs review of our proposed program helped validate it and unlock investor funding.
The size and experience of the team allowed rapid progress, generating compounds suitable for further evaluation in our primary indications and allowed us to (successfully!) explore radically new applications of our technology.

Chris Moody
Co-Founder

The o2h Kickstarter competition promises to be an excellent scheme allowing early-stage companies like ours to get access to synthetic chemistry.

Vid Stojevic
CEO & Co-Founder

The Kickstarter provides vital access to chemists with the skills and knowledge to deliver on the promise of our technology.

Dr Janette A Thomas
CEO

I am thrilled that Five Alarm Bio has been awarded the Kickstarter program. We will benefit from the extensive knowledge and enthusiasm of the o2h leadership and laboratory scientists.

Beth J Hoffman
President & CEO

The Kickstarter will enable us to thoroughly explore our nascent SAR and advance our lead program more rapidly.

Gert Kiss
Co-Founder & CEO

o2h’s Kickstarter Award has substantially accelerated our lead-series expansion plans, thanks to a professional team that has been over-delivering on some rather challenging and exciting chemistry.

Mathew Gray-Davies
Director

We're delighted to receive o2h's Kickstarter award this year. Our primary mission is developing therapeutics to safely target processes shared by many neurodegenerative diseases as well as chronic cognitive, fatigue, and pain disorders. o2h's support of this mission is truly inspiring, and the expertise of their chemistry and biology teams serves as a vital catalyst for our first two discovery projects.

Dr Ramsay McFarlane
Co-Founder & CEO

We have been fortunate enough to work with the outstanding o2h Kickstarter team, which has enabled us to move rapidly through our compound screening programme in an exceptionally cost-effective fashion. The o2h team bring great depth of expertise and experience of the pharmaceutical sector, with a strong understanding of our specific needs. The whole o2h team has worked efficiently and diligently, with high quality end results that are enabling us to reach for our long-terms goals to bring new therapeutics to cancer patients.

Dr Nat Hastings
Chief Executive Officer

At Cellestial, our goal is to maximise patient benefit that our treatments can offer. Small molecule therapeutics remain the most scalable form of treatment modality, meaning that more people around the world can benefit from them. We are proud to partner with o2h to expand our pipeline of astrocyte-protective small molecule drugs. The expertise provided both on the conceptual planning stage as well as the synthesis efficiency is world-class.

David Barlow
Chair & CEO

We’re honored to receive o2h’s Kickstarter Award, a meaningful validation of our novel program addressing debilitating symptoms of Parkinson’s Disease. Psy's collaboration with o2h's superb chemistry team will further accelerate this high-impact program’s path to the clinic and advance our broader mission to deliver transformative treatments to patients in need.
benefits
team
A dedicated team of six FTE synthetic chemists of which two are experienced and four are trainees.
cost & duration
Six synthetic chemists at a fraction of the usual price for up to six months.

additional support
Receive 100 complimentary ADME points and save 20% on Biology FTE.
inventory
Access to a large inventory of chemicals and reagents for synthesis.
eligibility
The competition is for pre-seed stage small molecule focused biotech companies which have secured initial funding from recognized grant bodies or venture/angel investors, has exciting drug targets and ability to scale.
Know moreevaluation
The applications will be evaluated by the o2h Kickstarter committee and 3 winners will be announced soon. This is a time limited competition. If supportive to the global biotech ecosystem we will run this again.